Cure My Disease

Don't miss your cure!

 Log in / Sign up

A diet tweak may boost platelets in a bleeding disorder

NCT ID NCT07798050

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This trial tests whether adding a selective Mediterranean diet to standard treatment can improve platelet counts and reduce bleeding in adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. Sixty adults aged 18 to 60 with low platelet counts will be randomly assigned to either the diet plus standard therapy or standard therapy alone. Over 12 weeks, researchers will measure changes in platelet counts and bleeding severity to see if the diet offers extra benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A selective Mediterranean diet regimen, used alongside standard ITP medications such as corticosteroids or intravenous immunoglobulin
What this could lead to
If it works, this diet could become a simple, safe addition to standard ITP treatment, helping patients raise their platelet counts and reduce bleeding without extra drugs.
What could go wrong
This is a small, early-stage trial, so the diet may not meaningfully improve platelet counts or bleeding. Dietary changes can be hard to follow, and results may not apply to all ITP patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-60 years * Diagnosis of primary immune thrombocytopenia according to American Society of Hematology (ASH) criteria * Platelet count \< 100 × 10⁹/L at enrollment * Willingness to comply with the dietary protocol and follow-up schedule Exclusion Criteria: * Secondary thrombocytopenia * Pregnancy or lactation * Uncontrolled diabetes mellitus, chronic kidney disease, or hepatic failure * Strict dietary regimens for other medical conditions * History of bariatric surgery or malabsorption syndromes * Known food allergies to core Mediterranean diet components * Active chemotherapy or splenectomy within the last 3 months * Prednisone/prednisolone ≥ 20 mg/day (or equivalent) at enrollment or recent dose adjustment within 2 weeks * Poor compliance or inability to attend follow-up visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic thrombocytopenic purpura are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic thrombocytopenic purpura Immune thrombocytopenia Thrombocytopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.